Induction of p53 DNA-binding activity by tumor necrosis factor-α

International Journal of Oncology

Volumn 9, Issue 4, 1996, Pages 715-720

  Mukhopadhyay, Tapas ^a   Roth, Jack A ^a   Maxwell, Steve A ^b,c  

^a UNIVERSITY OF TEXAS   (United States)

^b TEXAS A AND M UNIVERSITY   (United States)

^c TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

Author keywords

NSCLC; p53; post translation; regulation; TNF

Indexed keywords

PROTEIN P53; TRANSCRIPTION FACTOR; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CELL LINE; CONTROLLED STUDY; DNA BINDING; HUMAN; HUMAN CELL; LUNG CARCINOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; SPECIES DIFFERENCE;

EID: 0029816979     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. Hollstein M, Sidransky D, Vogelstein B and Harris C: p53 mutations in human cancer. Science 253: 49-53, 1991.
2. Landanyi M, Cha C, Lewis R, Jhanwar SC, Huvos AG and Healy JH: MDM2 gene amplification in metastatic osteosarcoma. Cancer Res 53: 16-18, 1993.
3. Sheikh MS, Shao Z-M, Hussain A and Fontana JA: The p53-binding protein MDM2 gene is differentially expressed in human breast carcinoma. Cancer Res 53: 3226-3228, 1993.
4. Momand J, Zambetti GP, Olson DC, George D and Levine AJ: The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 69: 1237-1245, 1992.
5. Finlay CA: The mdm-2 oncogene can overcome wild-type p53 suppression of transformed cell growth. Mol Cell Biol 13: 301-306, 1993.
6. Finlay CA, Hinds PW and Levine AJ: The p53 proto-oncogene can act as a suppressor of transformation. Cell 57: 1083-1093, 1989.
7. Baker SJ, Markowitz S, Fearon ER, Willson JKV and Vogelstein B: Suppression of human colorectal cell growth by wild-type p53. Science 249: 912-915, 1990.
8. Johnson T, Gray D, Mowat M and Benchimol S: Expression of wild-type p53 is not compatible with continued growth of p53-negative cells. Mol Cell Biol 11: 1-11, 1991.
9. Bendori R, Resnitzky D and Kimchi A: Changes in p53 mRNA expression during terminal differentiation of murine erythroleukemia cells. Virology 161: 607-611, 1987.
10. Oren M, Reich NC and Levine AJ: Regulation of the cellular p53 tumor antigen in teratocarcinoma cells and their differentiated projeny. Mol Cell Biol 2: 443-449, 1983.
11. Aloni-Grinstein R, Zan-Bar I, Alboum I, Goldfinger N and Rotter V: Wild-type p53 functions as a control protein in the differentiation pathway of the B-cell lineage. Oncogene 8: 3297-3305, 1993.
12. Yonish-Rouach E, Grunwald D, Wilder S, Kimchi A, May E, Lawrence J-J, May P and Oren M: p53-mediated cell death: relationship to cell cycle control. Mol Cell Biol 13: 1415-1423, 1993.
13. Debbas M and White E: Wild-type p53 mediates apoptosis by E1A, which is inhibited by E1B. Gene Develop 7: 546-554, 1993.
14. Clarke AR, Purdie CA, Harrison DJ, Morris RG, Bird CC, Hooper ML and Wyllie AH: Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature 362: 849-852, 1993.
15. Gottlieb E, Haffner R, Von Ruden T, Wagner EF and Oren M: Downregulation of wild-type p53 actively interferes with apoptosis of IL-3 dependent hematopoietic cells following IL-3 withdrawal. EMBO J 13: 1368-1374, 1994.
16. Merritt AJ, Potten CS, Kemp CJ, Hickman JA, Balmain A, Lane DP and Hall PA: The role of p53 in spontaneous and radiation-induced apoptosis in the gastrointestinal tract of normal and p53-deficient mice. Cancer Res 54: 614-617, 1994.
17. Lane DP: p53, guardian of the genome. Nature 358: 15-16, 1992.
18. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B and Craig R: Participation of the p53 protein in the cellular response to DNA damage. Cancer Res 51: 6304-6311, 1991.
19. Zhan Q, Carrier F and Fornace AJ: Induction of cellular p53 activity by DNA-damaging agents and growth arrest. Mol Cell Biol 13: 4242-4250, 1993.
20. Livingstone LR, White A, Sprouse J, Livanos E, Jacks T and Tlsty TD: Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53. Cell 70: 923-925, 1992.
21. Yin Y, Tainsky MA, Bischoff FZ, Strong LC and Wahl GM: Wild-type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles. Cell 70: 937-948, 1992.
22. Fields S and Jang SK: Presence of a potent transcription activating sequence in the p53 protein. Science 249: 1046-1048, 1990.
23. Raycroft L, Wu H and Lozano G: Transcriptional activation by wild-type but not transforming mutants of the p53 anti-oncogene. Science 249: 1049-1051, 1990.
24. Funk WD, Pak DJ, Karas RH, Wright WE and Shay JW: A transcriptionally active DNA-binding site for human p53 protein complexes. Mol Cell Biol 12: 2866-2871, 1992.
25. Zambetti GP, Bargonetti J, Walker K, Prives C and Levine AJ: Wild-type p53 mediates positive regulation of gene expression through a specific DNA sequence element. Gene Develop 6: 1143-1152, 1992.
26. Zambetti GP and Levine AJ: A comparison of the biological activities of wild-type and mutant p53. FASEB J 7: 855-865, 1993.
27. Agoff SN, Hou J, Linzer DIH and Wu B: Regulation of the human hsp70 promoter by p53. Science 259: 84-87, 1993.
28. Martin DW, Munoz RM, Subler MA and Deb S: p53 binds to the TATA-binding protein-TATA complex. J Biol Chem 268: 13062-13067, 1993.
29. Maheswaran S, Park S, Bernard A, Morris JF, Rauscher J, Hill DE and Haber DA: Physical and functional interaction between WT1 and p53 proteins. Proc Natl Acad Sci USA 90: 5100-5104, 1993.
30. II31 protein is a transcriptional coactivator of the p53 protein. Proc Natl Acad Sci USA 92: 5154-5158, 1995.
31. II60. Science 267: 100-104, 1995.
32. Gannon JV and Lane DP: p53 and DNA polymerase a compete for binding to SV40 T antigen. Nature 329: 456-458, 1991.
33. Wang EH, Friedman PN and Prives C: The murine p53 protein blocks replication of SV40 DNA in vitro by inhibiting the initiation functions of SV40 large T antigen. Cell 57: 379-392, 1989.
34. Bargonetti J, Friedman PN, Kern SE, Vogelstein B and Prives C: Wild-type but not mutant p53 immunopurified proteins bind to sequences adjacent to the SV40 origin of replication. Cell 65: 1083-1091, 1991.
35. Dutta A, Ruppert JM, Aster JC and Winchester E: Inhibition of DNA replication factor RPA by p53. Nature 365: 79-82, 1993.
36. Cox LS, Hupp T, Midgley CA and Lane DP: A direct effect of activated human p53 on nuclear DNA replication. EMBO J 14: 2099-2105, 1995.
37. Ronen D, Rotter V and Reisman D: Expression from the murine p53 promoter is mediated by factor binding to a downstream helix-loop-helix recognition motif. Proc Natl Acad Sci USA 88: 4128-4132, 1991.
38. Reisman D and Rotter V: The helix-loop-helix containing transcription factor USF binds to and transactivates the promoter of the p53 tumor suppressor gene. Nucleic Acids Res 21: 345-350, 1993.
39. Deffie A, Wu H, Reinke V and Lozano G: The tumor suppressor p53 regulates its own transcription. Mol Cell Biol 13: 3415-3423, 1993.
40. Wu H and Lozano G: NF-κB activation of p53. A potential mechanism for suppressing cell growth in response to stress. J Biol Chem 269: 20067-20074, 1994.
41. Mitsudomi T, Steinberg SM, Nau MM, Carbone D, D'Amico D, Bodner S, Oie HK, Linnoila RI, Mulshine JL, Minna JD and Gazdar AF: p53 gene mutations in non-small cell lung cancer cell lines and their correlation with the presence of ras mutations and clinical features. Oncogene 7: 171-180, 1992.
42. Takahashi T, Nau MM, Chiba I, Birrer MJ, Rosenberg RK, Vinocour M, Levitt M, Pass H, Gazdar AF and Minna JD: p53: a frequent target for genetic abnormalities in lung cancer. Science 246: 491-494, 1989.
43. Maxwell SA and Mukhopadhyay T: Transient stabilization of p53 in non-small cell lung carcinoma cultures arrested for growth by retinoic acid. Exp Cell Res 214: 67-74, 1994.
44. Nabel G and Baltimore D: An inducible transcription factor activates expression of human immunodeficiency virus in T cells. Nature 326: 711-713, 1987.
45. Tewari M, Dobrzanski P, Mohn KL, Cressman DE, Hsu J-C, Bravo R and Taub R: Rapid induction in regenerating liver of RL/IF-1 (an I-κB that inhibits NF-κB, RelB-p50, and c-Rel-p50) and PHF, a novel xB site-binding complex. Mol Cell Biol 12: 2898-2908, 1992.
46. Fujita T, Nolan G, Ghosh S and Baltimore D: Independent modes of transcriptional activation by the p50 and p65 subunits of NF-κB. Gene Develop 6: 775-787, 1992.
47. Malik ST, Naylor MS, East N, Oliff A and Balkwill FR: Cells secreting tumour necrosis factor show enhanced metastasis in nude mice. Eur J Cancer 26: 1031-1034, 1990.
48. Lollini PL, De Giovanni C, Nicoletti G, Bontadini A, Tazzari PL, Landuzzi L, Scotlandi K and Nanni P: Enhancement of experimental metastatic ability by tumor necrosis-α alone or in combination with interferon-γ. Clin Exp Metastasis 8: 215-224, 1990.
49. Orosz P, Echtenacher B, Falk W, Ruschoff J, Weber D and Mannel DN: Enhancement of experimental metastasis by tumor necrosis factor. J Exp Med 177: 1391-1398, 1993.
50. Saiki I, Maeda H, Murata J, Yamamoto N, Kiso M, Hasegawa A and Azuma I: Antimetastatic effect of endogenous tumor necrosis factor induced by treatment of recombinant interferon-γ followed by an analog (GLA-60) to synthetic lipid. A subunit. Cancer Immunol Immunother 30: 151-157, 1989.
51. Schultz RM and Altom MG: Protective activity of recombinant murine tumor necrosis factor-α and interferon-γ against experimental murine lung carcinoma metastases. J Interferon Res 10: 229-236, 1990.
52. Sylvester DM, Liu SY and Meadows GG: Augmentation of antimetastatic activity of interferon and tumor necrosis factor by heparin. Immunopharmacol Immunotoxicol 12: 161-180, 1990.